Orexigen continues to seek approval for its fixed-combination of naltrexone on bupropion, Contrave.
FORBES: Why Does Arena's Obesity Drug Have Abuse Potential?
The biggest loser was Orexigen, whose obesity drug Contrave was rejected by the FDA on Feb 1.
FORBES: Biotech Busts And Breakthroughs For February
Orexigen still has a lot of work to do, and there is no assurance that Contrave will be approved.
FORBES: Orexigen Lives Again!
应用推荐
模块上移
模块下移
不移动